Product Details
GAVRETO 100MG CAP 60/EA
Manufacturer: GENENTECH, INC
MFG#: 50242-0210-60
NDC: 50242-0210-60
PID: 422223
Additional Information
| Product Name | Gavreto 100 mg Cap 60/Ea |
| Application | Targeted Cancer Therapy |
| Generic Drug Name | Pralsetinib |
| Mechanism of Action | Selective inhibition of RET kinase, blocking tumor cell proliferation and survival |
| Strength | 100 mg |
| Type | Kinase Inhibitor |
| Volume | 60 Capsules |
| Administration Route | Oral |
| Metabolism | Primarily metabolized in the liver via CYP3A4 enzyme |
| Elimination | Excreted through feces and urine |
| Adverse Effects | Hypertension, hepatotoxicity, myelosuppression, interstitial lung disease, fatigue |
| Drug Interactions | Avoid strong CYP3A inhibitors or inducers due to altered drug metabolism |
| Uses | Treatment of RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) |
Description
Gavreto (pralsetinib) 100 mg capsules are an oral kinase inhibitor used for the treatment of specific cancers associated with RET gene alterations. It is indicated for patients with non-small cell lung cancer (NSCLC), thyroid cancer, and other RET fusion-positive solid tumors. As a targeted therapy, it selectively inhibits rearranged during transfection (RET) kinase activity, preventing cancer cell proliferation and tumor growth.
The mechanism of action involves binding to the RET kinase domain, thereby blocking downstream signaling pathways involved in tumor cell survival and progression. By inhibiting RET-driven oncogenesis, Gavreto reduces tumor burden and may enhance patient survival. The therapy is used in cases where tumors are resistant to conventional treatments or when surgery is not a viable option.
Gavreto is associated with potential adverse effects, including hypertension, hepatotoxicity, interstitial lung disease, and myelosuppression. Regular monitoring of liver enzymes, blood pressure, and complete blood counts is required to mitigate risks. Dose adjustments or treatment interruptions may be necessary if severe toxicities occur.
Frequently Asked Questions (FAQs)
The cost of GAVRETO 100MG CAP 60/EA is $available for registerd members only
GAVRETO 100MG CAP 60/EA is manufactured by GENENTECH, INC.
You can purchase GAVRETO 100MG CAP 60/EA on our website at https://supplies.pipelinemedical.com/product/detail/gavreto-100mg-cap-60-ea-422223